GoodRx Holdings, Inc. (GDRX) officer details RSU and share moves

Rhea-AI Filing Summary

GoodRx Holdings, Inc. officer Romin Nabiey, the Chief Accounting Officer, reported equity transactions dated December 8, 2025. He acquired 10,200 and 2,232 shares of Class A common stock through the vesting and settlement of restricted stock units and disposed of 3,650 and 799 shares at $2.71 per share.

After these transactions, Nabiey directly beneficially owns 165,475 shares of Class A common stock. He also continues to hold restricted stock units representing 30,603 and 20,091 underlying shares, which vest 6.25% initially and then in approximately equal quarterly installments over 15 quarters starting on December 8, 2022 and June 8, 2024, respectively.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nabiey Romin

(Last) (First) (Middle)

C/O GOODRX HOLDINGS, INC.

2701 OLYMPIC BOULEVARD

(Street)

SANTA MONICA CA 90404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GoodRx Holdings, Inc. [ GDRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/08/2025		M		10,200	A	(1)	167,692	D
Class A Common Stock	12/08/2025		F		3,650	D	$2.71	164,042	D
Class A Common Stock	12/08/2025		M		2,232	A	(1)	166,274	D
Class A Common Stock	12/08/2025		F		799	D	$2.71	165,475	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	12/08/2025		M			10,200	(2)	(2)	Class A Common Stock	10,200	$0	30,603	D
Restricted Stock Unit	(1)	12/08/2025		M			2,232	(3)	(3)	Class A Common Stock	2,232	$0	20,091	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Class A common stock.

2. The restricted stock unit award vested as to 6.25% of the underlying shares on December 8, 2022 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.

3. The restricted stock unit award will vest as to 6.25% of the underlying shares on June 8, 2024 with the remaining 93.75% vesting in approximately equal quarterly installments thereafter for 15 quarters.

Remarks:

	/s/ Gracye Cheng, Attorney-in-Fact for Romin Nabiey	12/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider share transactions did GoodRx (GDRX) report for Romin Nabiey on December 8, 2025?

On December 8, 2025, Chief Accounting Officer Romin Nabiey acquired 10,200 and 2,232 shares of GoodRx Class A common stock through restricted stock unit settlements and disposed of 3,650 and 799 shares at $2.71 per share.

How many GoodRx (GDRX) Class A shares does Romin Nabiey own after the reported Form 4 transactions?

Following the reported transactions, Romin Nabiey directly beneficially owns 165,475 shares of GoodRx Class A common stock.

What restricted stock unit (RSU) holdings does the GoodRx (GDRX) officer still have after these transactions?

After the transactions, Nabiey holds restricted stock units covering 30,603 and 20,091 underlying shares of GoodRx Class A common stock.

How do Romin Nabiey’s GoodRx (GDRX) RSUs vest over time?

One RSU award vested as to 6.25% of the shares on December 8, 2022, with the remaining 93.75% vesting in approximately equal quarterly installments over 15 quarters. The second RSU award will vest as to 6.25% of the shares on June 8, 2024, with the remaining 93.75% vesting in approximately equal quarterly installments over 15 quarters.

What do the transaction codes M and F mean in the GoodRx (GDRX) insider report?

In the report, transaction code M is used for the settlement of restricted stock units into Class A common stock, and code F is used for dispositions of shares at $2.71 per share.